Shares of Ibiden Co Ltd (TYO:4062) soared on Tuesday after the electronics firm was officially selected to join Japan’s Nikkei 225 index, replacing Nidec Corp (TYO:6594). The announcement sparked a sharp contrast in market performance between the two companies, highlighting investor sentiment surrounding the index reshuffle and ongoing corporate governance concerns.
Ibiden’s stock jumped as much as 21% to a record high of ¥13,145, significantly outperforming the Nikkei 225, which dipped 0.2% on the day. The addition of Ibiden to Japan’s benchmark index, effective November 5, signals growing confidence in the company’s business outlook and market relevance in the electronics sector. Investors often view inclusion in the Nikkei 225 as a positive sign, given the potential for increased exposure among institutional funds that track the index.
In stark contrast, Nidec shares tumbled nearly 20% to ¥2,123.5, hitting their lowest level in six months. The electric motor manufacturer not only lost its place in the Nikkei 225 but will also be removed from other major indexes, including the Nikkei Stock Index 300 and the 500 Stock Average. The steep decline followed the company’s designation as a “security on special alert”, as the exchange called for stronger internal controls amid an investigation into alleged irregular accounting practices.
Earlier this month, Nidec also canceled a planned share buyback program due to the ongoing probe, intensifying investor concerns about transparency and financial management. The company now faces significant pressure to restore market confidence and demonstrate corrective action. Meanwhile, Ibiden’s rise underscores how index inclusion can serve as a catalyst for investor optimism and capital inflows in Japan’s equity markets.


SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 



